159837 生物科技
交易中 10-08 14:30:24
资讯
新帖
简况
小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO
智通财经 · 10-06 11:32
小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO
江苏中慧元通生物科技：独立法证调查及内控检讨进行中，H股继续停牌
同花顺 · 09-30
江苏中慧元通生物科技：独立法证调查及内控检讨进行中，H股继续停牌
共享基经丨14只生物科技ETF怎么选？港股、A股赛道有何不同？
每日经济新闻 · 09-30
共享基经丨14只生物科技ETF怎么选？港股、A股赛道有何不同？
【投融资动态】创构生物科技天使+融资，投资方为中关村资本、北洋海棠基金等
证券之星 · 09-29
【投融资动态】创构生物科技天使+融资，投资方为中关村资本、北洋海棠基金等
益方生物科技（688382）9月28日主力资金净买入246.74万元
证券之星 · 09-29
益方生物科技（688382）9月28日主力资金净买入246.74万元
康为世纪生物科技（688426）9月24日主力资金净卖出318.91万元
证券之星 · 09-25
康为世纪生物科技（688426）9月24日主力资金净卖出318.91万元
9月24日益方生物科技跌5.83%，汇添富创新医药混合A基金重仓该股
证券之星 · 09-24
9月24日益方生物科技跌5.83%，汇添富创新医药混合A基金重仓该股
康为世纪生物科技（688426）9月23日主力资金净买入815.00万元
证券之星 · 09-24
康为世纪生物科技（688426）9月23日主力资金净买入815.00万元
【ETF动向】9月22日生物科技ETF易方达基金跌0.19%，份额减少7900万份
证券之星 · 09-23
【ETF动向】9月22日生物科技ETF易方达基金跌0.19%，份额减少7900万份
腾盛博药生物科技于联交所回购3万股 每股作价0.86港元
同花顺 · 09-18
腾盛博药生物科技于联交所回购3万股 每股作价0.86港元
【ETF动向】9月17日生物科技ETF易方达基金涨0.62%，份额增加1.42亿份
证券之星 · 09-18
【ETF动向】9月17日生物科技ETF易方达基金涨0.62%，份额增加1.42亿份
四川双马：CDMO业务成功切入欧美主流市场，已与美、欧多家知名生物科技公司建立合作
财闻 · 09-15
四川双马：CDMO业务成功切入欧美主流市场，已与美、欧多家知名生物科技公司建立合作
生物科技公司Electra Therapeutics(ETRA.US)IPO定价14-16美元/股 拟筹资3.25亿美元
智通财经 · 09-15
生物科技公司Electra Therapeutics(ETRA.US)IPO定价14-16美元/股 拟筹资3.25亿美元
股市必读：贝泰妮新发布《北京市君合律师事务所关于云南贝泰妮生物科技集团股份有限公司2026年第二次临时股东会的法律意见书》
证券之星 · 09-11
股市必读：贝泰妮新发布《北京市君合律师事务所关于云南贝泰妮生物科技集团股份有限公司2026年第二次临时股东会的法律意见书》
从美妆到生物科技公司 植物医生挺进大健康领域
同花顺 · 09-07
从美妆到生物科技公司 植物医生挺进大健康领域
从护肤到大健康，植物医生想成为一家生物科技公司
蓝鲸财经 · 09-04
从护肤到大健康，植物医生想成为一家生物科技公司
【新股IPO】维眸生物科技向港交所主板提交上市申请
金吾财讯 · 08-31
【新股IPO】维眸生物科技向港交所主板提交上市申请
Electra Therapeutics(ETRA.US)递交美股IPO申请，借生物科技上市热潮推进免疫疾病与癌症新药研发
智通财经 · 08-29
Electra Therapeutics(ETRA.US)递交美股IPO申请，借生物科技上市热潮推进免疫疾病与癌症新药研发
港股IPO：维眸生物科技（浙江）股份有限公司-B递表港交所
同花顺 · 08-28
港股IPO：维眸生物科技（浙江）股份有限公司-B递表港交所
英国风险投资强劲反弹 软件与生物科技领跑融资
环球市场播报 · 08-28
英国风险投资强劲反弹 软件与生物科技领跑融资
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159837","market":"SZ","secType":"STK","nameCN":"生物科技","latestPrice":0.498,"timestamp":1791441024000,"preClose":0.517,"halted":0,"volume":80461930,"delay":0,"changeRate":-0.0368,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-0.019,"latestTime":"10-08 14:30:24","open":0.52,"high":0.52,"low":0.498,"amount":40794400,"amplitude":0.0426,"askPrice":0.498,"askSize":17958,"bidPrice":0.497,"bidSize":199796,"shortable":0,"etf":1,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791442800000},"marketStatusCode":2,"adr":0,"adjPreClose":0.517,"symbolType":"fund","openAndCloseTimeList":[[1791423000000,1791430200000],[1791435600000,1791442800000]],"highLimit":0.569,"lowLimit":0.465,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.414897,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159837/wiki","defaultTab":"wiki","newsList":[{"id":"2673035134","title":"小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673035134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673035134?lang=zh_cn&edition=full","pubTime":"2026-10-06 11:32","pubTimestamp":1791257520,"startTime":"0","endTime":"0","summary":"另外，该行预期本轮加息周期将于12月再加息一次后结束，而非延续至明年的长期紧缩，因此对利率上升影响中国医疗健康估值并不太担心，并继续看好生物科技及CXO子板块。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FTXO","WX","TRUF","KBWB","02269","LNGR","03696","LU0976567544.SGD","XLF","EQRR","02359","LU0708995153.HKD","LU0345769631.USD","IYG","JPMO","PEX","JPO","VFH","MEDX","XLBI","HBImain","LU2168564065.EUR","159837","KURE","IE00BKDWB100.SGD","LABU","LU0572944931.SGD","VHT","IBBJ","AGNG","IYF","FNCL","LU1670627923.USD","XLV","IXG","CXO","LU1974910355.USD","TFNS","IEIH","02268","XBI","06990","SYNB","IE0034235295.USD","GDOC","159760","IXJ","UYG","01548","LU0345769128.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671202809","title":"江苏中慧元通生物科技：独立法证调查及内控检讨进行中，H股继续停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2671202809","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671202809?lang=zh_cn&edition=full","pubTime":"2026-09-30 20:41","pubTimestamp":1790772060,"startTime":"0","endTime":"0","summary":"9月30日，中慧生物-B(02627.HK)公布复牌进展。联交所此前已载列复牌指引，要求就基金投资及咨询款项进行独立法证调查、委聘独立内控顾问进行内控检讨、刊发尚未刊发的财务业绩并证明公司符 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260930/c680423250.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260930/c680423250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671208951","title":"共享基经丨14只生物科技ETF怎么选？港股、A股赛道有何不同？","url":"https://stock-news.laohu8.com/highlight/detail?id=2671208951","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671208951?lang=zh_cn&edition=full","pubTime":"2026-09-30 17:51","pubTimestamp":1790761879,"startTime":"0","endTime":"0","summary":"9月30日，A股主要指数走势分化，上证指数收涨0.31%，深证成指、创业板指小幅收跌。盘面上，医药生物板块表现突出，CRO、重组蛋白、疫苗、细胞免疫治疗等细分赛道涨幅居前。港股方面，恒生指数小幅上涨，港股生物技术、CXO板块成为市场主线。从ETF来看，疫苗、生物科技、港股创新药、医疗主题相关ETF涨幅居前。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://stock.eastmoney.com/a/202609303887797810.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/a/202609303887797810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","02823","AGNG","BK4588","03188","IBBJ","83188","BK4550","02843","XBI","82822","03130","BK4581","GDOC","399300","83130","VXUS","IEIH","FDN","BK4585","159837","02822","07233","82823","82843","BK1610","MEDX","BK1147","159982","82846","02827","KCAI","02846","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671873219","title":"【投融资动态】创构生物科技天使+融资，投资方为中关村资本、北洋海棠基金等","url":"https://stock-news.laohu8.com/highlight/detail?id=2671873219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671873219?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:26","pubTimestamp":1790681215,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于9月21日公布的信息整理，北京创构生物科技有限公司天使+融资，融资额未披露，参与投资的机构包括中关村资本，北洋海棠基金。北京创构生物科技有限公司成立于2025年，是一家以合成生物学技术为核心，从事绿色天然产物研发、生产与销售的一体化生物制造创新型企业。公司依托北京化工大学袁其朋教授课题组在莽草酸通路领域历经15年的技术沉淀，启动该通路上一系列芳香族化合物的产业化开发。数据来源：天眼查APP以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900034302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0028","000931","159837","BK0178","BK0239","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671269689","title":"益方生物科技（688382）9月28日主力资金净买入246.74万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671269689","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671269689?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:38","pubTimestamp":1790642312,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，益方生物科技报收于17.65元，下跌5.87%，换手率2.79%，成交量16.16万手，成交额2.88亿元。近5日资金流向一览见下表：益方生物科技融资融券信息显示，融资方面，当日融资买入1851.88万元，融资偿还807.14万元，融资净买入1044.74万元，连续3日净买入累计1897.76万元。益方生物科技主营业务：致力于研制出具有自主知识产权、中国创造并面向全球的创新药物,持之以恒地为患者提供更加安全、有效、可负担的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HBImain","BK0239","688382","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419992","title":"康为世纪生物科技（688426）9月24日主力资金净卖出318.91万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419992?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:22","pubTimestamp":1790295736,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，康为世纪生物科技报收于21.96元，下跌7.69%，换手率3.76%，成交量4.22万手，成交额9528.14万元。近5日资金流向一览见下表：康为世纪生物科技融资融券信息显示，融资方面，当日融资买入860.48万元，融资偿还626.98万元，融资净买入233.5万元。康为世纪生物科技主营业务：分子检测底层核心技术的自主研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159837","HBImain","688426","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146392","title":"9月24日益方生物科技跌5.83%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669146392?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:38","pubTimestamp":1790239124,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日益方生物科技跌5.83%，收盘报18.75元，换手率1.84%，成交量10.68万手，成交额2.03亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共41家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为89.62亿元，最新净值1.72，较上一交易日下跌0.4%，近一年下跌14.37%。汇添富创新医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","09939","159837","BK1161","HBImain","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669432756","title":"康为世纪生物科技（688426）9月23日主力资金净买入815.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669432756","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669432756?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:14","pubTimestamp":1790208843,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月23日收盘，康为世纪生物科技报收于23.79元，上涨7.99%，换手率5.25%，成交量5.9万手，成交额1.41亿元。近5日资金流向一览见下表：康为世纪生物科技融资融券信息显示，融资方面，当日融资买入1293.17万元，融资偿还803.94万元，融资净买入489.23万元。康为世纪生物科技主营业务：分子检测底层核心技术的自主研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400007634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688426","BK0239","HBImain","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669173896","title":"【ETF动向】9月22日生物科技ETF易方达基金跌0.19%，份额减少7900万份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669173896","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669173896?lang=zh_cn&edition=full","pubTime":"2026-09-23 08:02","pubTimestamp":1790121738,"startTime":"0","endTime":"0","summary":"证券之星消息，9月22日，生物科技ETF易方达基金（159837）跌0.19%，成交额3903.82万元。当日份额减少了7900万份，最新份额为29.89亿份，近20个交易日份额增加1.97亿份。当日资金净流出4170.69万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为15.32亿元。生物科技ETF易方达基金跟踪标的为中证生物科技主题指数，成立（2021-01-14）以来超额回报为3.58%，近一个月超额回报为0.28%，管理人为易方达基金公司，基金经理为张湛 陈英嘉。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300006878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159837","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668925903","title":"腾盛博药生物科技于联交所回购3万股 每股作价0.86港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668925903","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668925903?lang=zh_cn&edition=full","pubTime":"2026-09-18 20:32","pubTimestamp":1789734720,"startTime":"0","endTime":"0","summary":"9月18日，腾盛博药-B(02137.HK)在香港联合交易所回购30,000股普通股，每股购回价为HKD0.86，付出的价格总额为HKD25,800。回购股份被持作库存股份，拟注销数目为0。此次回购占有关事件前已发 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260918/c680074282.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260918/c680074282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668913892","title":"【ETF动向】9月17日生物科技ETF易方达基金涨0.62%，份额增加1.42亿份","url":"https://stock-news.laohu8.com/highlight/detail?id=2668913892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668913892?lang=zh_cn&edition=full","pubTime":"2026-09-18 08:05","pubTimestamp":1789689908,"startTime":"0","endTime":"0","summary":"证券之星消息，9月17日，生物科技ETF易方达基金（159837）涨0.62%，成交额2253.8万元。当日份额增加了1.42亿份，最新份额为29.71亿份，近20个交易日份额增加2.52亿份。当日资金净流入7853.39万元（资金流向是当日计算的资产净值和上一交易日计算的资产净值相减得出的），最新资产净值计算值为14.54亿元。生物科技ETF易方达基金跟踪标的为中证生物科技主题指数，成立（2021-01-14）以来超额回报为3.42%，近一个月超额回报为0.37%，管理人为易方达基金公司，基金经理为张湛 陈英嘉。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091800004226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HBImain","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667236686","title":"四川双马：CDMO业务成功切入欧美主流市场，已与美、欧多家知名生物科技公司建立合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2667236686","media":"财闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667236686?lang=zh_cn&edition=full","pubTime":"2026-09-15 21:31","pubTimestamp":1789479060,"startTime":"0","endTime":"0","summary":"9月15日，四川双马(000935.SZ)发布投资者关系活动记录表。其中指出，CDMO业务成功切入欧美主流市场，已与美国、欧洲多家知名生物科技公司建立合作。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-15/doc-inirxpis3668545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","AGNG","BK4588","BK0004","IBBJ","XBI","BK4581","GDOC","BK4139","IEIH","BK0028","BK4585","159837","MEDX","BK0021","BK0235","000935","SYNB","HBImain","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667612838","title":"生物科技公司Electra Therapeutics(ETRA.US)IPO定价14-16美元/股 拟筹资3.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667612838","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667612838?lang=zh_cn&edition=full","pubTime":"2026-09-15 15:18","pubTimestamp":1789456715,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发靶向SIRP抗体、用于免疫疾病和癌症治疗的II/III期的生物科技公司Electra Therapeutics周一公布了首次公开募股的发行条款。Electra Therapeutics正在开发一类精准药物，靶向特定免疫细胞群体上表达的信号调节蛋白。Electra Therapeutics欲借今年生物科技板块IPO强劲表现的东风，为其处于临床阶段的免疫介导疾病和癌症药物管线筹集资金。汇编数据显示，今年美国生物科技与制药公司的IPO累计募资额已达68亿美元，平均加权回报率接近70%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGNG","ETRA","IBBJ","159837","XBI","UDN","LNGR","BK4585","BK4007","BK4581","GDOC","IEIH","MEDX","LENZ","IPOS","BK4139","BK4588","SYNB","UUP","HBImain","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666659746","title":"股市必读：贝泰妮新发布《北京市君合律师事务所关于云南贝泰妮生物科技集团股份有限公司2026年第二次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666659746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666659746?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:07","pubTimestamp":1789060030,"startTime":"0","endTime":"0","summary":"公司公告汇总北京市君合律师事务所关于云南贝泰妮生物科技集团股份有限公司2026年第二次临时股东会的法律意见书北京市君合律师事务所就云南贝泰妮生物科技集团股份有限公司2026年第二次临时股东会的召集和召开程序、出席人员资格、召集人资格、表决程序及表决结果出具法律意见书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100001980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300957","HBImain","BK0229","159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665962333","title":"从美妆到生物科技公司 植物医生挺进大健康领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2665962333","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665962333?lang=zh_cn&edition=full","pubTime":"2026-09-07 11:46","pubTimestamp":1788752760,"startTime":"0","endTime":"0","summary":"渠道红利退去、流量成本攀升、产品同质化加剧……中国美妆行业正经历从“快车道”到“窄门”的残酷转型。当“一招鲜”的战术红利消失，建立底层技术壁垒不再是可选项，而是生存项。当全行业 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260907/c679648733.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260907/c679648733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["GDOC","IEIH","MEDX","AGNG","BK4588","BK4585","SYNB","HBImain","BK4581","XBI","IBBJ","159837","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381446","title":"从护肤到大健康，植物医生想成为一家生物科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381446","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664381446?lang=zh_cn&edition=full","pubTime":"2026-09-04 12:39","pubTimestamp":1788496793,"startTime":"0","endTime":"0","summary":"从高山植物护肤，到中国原创成分，再到大健康产品，它正在尝试把高山植物科研从服务于单一护肤品的研发能力，变成一套能够跨品类持续产生价值的科研底座。这个问题的答案，将决定植物医生最终是增加了一条大健康产品线，还是能够真正完成从护肤品牌向生物科技公司的能力跃迁。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788496062591431273","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4581","BK4588","159837","AGNG","IBBJ","XBI","SYNB","MEDX","BK4585","GDOC","IEIH","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663023248","title":"【新股IPO】维眸生物科技向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2663023248","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663023248?lang=zh_cn&edition=full","pubTime":"2026-08-31 09:06","pubTimestamp":1788138403,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所8月28日披露，维眸生物科技向港交所主板提交上市申请，中金公司为独家保荐人。公司成立于2016年，是一家聚焦眼科领域的临床阶段生物科技企业。公司拥有两款核心产品VVN461（高剂量）及VVN001。公司拟将集资所得用于核心产品VVN461（高剂量）的开发；VVN001的临床开发及注册；其他候选产品的开发及注册；组建内部商业化团队及营销活动；及营运资金及其他一般企业用途。","market":"hk","thumbnail":"https://static.szfiu.com/news/20220324/MmFjZGExNjQxMjAyMjczMTQ1Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/MmFjZGExNjQxMjAyMjczMTQ1Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989968","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LNGR","IPOS","FRHC","159837","MEDX","SYNB","IBBJ","BK4127","BK4588","HEXmain","KCE","GDOC","IEIH","XBI","BK4585","AGNG","REDS","HBImain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663114360","title":"Electra Therapeutics(ETRA.US)递交美股IPO申请，借生物科技上市热潮推进免疫疾病与癌症新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2663114360","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663114360?lang=zh_cn&edition=full","pubTime":"2026-08-29 11:05","pubTimestamp":1787972713,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物科技公司Electra Therapeutics Inc.已正式递交首次公开募股申请，欲借今年生物科技板块IPO强劲表现的东风，为其处于临床阶段的免疫介导疾病和癌症药物管线筹集资金。截至今年6月30日，公司持有现金及现金等价物约9770万美元。其中，脱发治疗药物研发商Veradermics Inc.自2月上市以来股价飙升476%，领跑该板块。Electra此次IPO的主承销商包括杰富瑞金融集团、多伦多道明银行、Evercore Inc.和Cantor Fitzgerald。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LENZ","MEDX","IPOS","KCE","LNGR","BK4588","BK4127","AGNG","BK4539","XBI","SYNB","GDOC","BK4581","IBBJ","REDS","BK4139","HBImain","IEIH","159837","FRHC","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662093628","title":"港股IPO：维眸生物科技（浙江）股份有限公司-B递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2662093628","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662093628?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:34","pubTimestamp":1787920440,"startTime":"0","endTime":"0","summary":"每经AI快讯，8月28日，港交所文件显示，维眸生物科技（浙江）股份有限公司-B向港交所提交上市申请书，独家保荐人为中金公司。每日经济新闻 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260828/c679405461.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260828/c679405461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159837"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662065286","title":"英国风险投资强劲反弹 软件与生物科技领跑融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2662065286","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662065286?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:36","pubTimestamp":1787909760,"startTime":"0","endTime":"0","summary":"2026年上半年，英国风险投资总额达144亿英镑，全年有望突破2021年创下的260亿英镑纪录，创历史新高。PitchBook数据显示，今年英国风投中，英国本土投资者仅占融资总额的11%，为历史较低水平，美国买家历来占据主导地位。与此同时，英国富裕零售投资者对旨在激励早期企业融资的风投信托基金兴趣减弱。在具体交易方面，AI与生命科学公司Isomorphic Labs及自动驾驶技术集团Wayve成为今年融资主力，第二季度分别完成15亿和9.45亿英镑融资。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-08-28/doc-inipwhrt5802738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBJ","BK4588","BK4585","GDOC","VGT","XBI","159837","AGNG","SYNB","LNGR","159180","BK4581","IEIH","HBImain","MEDX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791441032294,"stockEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":0.0402},{"period":"3month","weight":0.1023},{"period":"6month","weight":0.0616},{"period":"1year","weight":-0.1024},{"period":"ytd","weight":0.0466}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,159837,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(159837)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(159837)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}